Mandate

Vinge advises Precio Fishbone in connection with the sale of shares in a subsidiary company

Vinge advises Precio Fishbone AB (publ) (”Precio Fishbone”) in connection with the sale of approximately 80.1 per cent of the shares in the subsidiary Precio Fishbone Systems AB ("Omnia"), including the product Omnia Digital Workplace, to Monterro.

Omnia Digital Workplace has been awarded in several different international contexts and has for six consecutive years been ranked as the market's best SaaS product for creating a modern digital workplace.

Monterro acquires a majority stake of approximately 80.1 per cent in Omnia from Precio Fishbone while Precio Fishbone retains a minority stake of approximately 19.9 per cent. Omnia has been created through a restructuring whereby all operations and employees related to the product Omnia Digital Workplace have been transferred from Precio Fishbone to the previously wholly owned subsidiary Omnia. All shares in Omnia are transferred to a company that will be indirectly owned by Monterro and Precio Fishbone. The purchase price for the approximately 80.1 per cent of the shares in Omnia indirectly transferred to Monterro amounts to SEK 168 million. Omnia also owns Omnia Systems Ltd (Vietnam), Precio Fishbone Canada Inc, Precio Fishbone Danmark ApS and has a branch in Germany.

Vinge’s team consisted of Matthias Pannier, Gustav Persson, Maximilian Bengtsson (M&A), Dain Hård Nevonen, William Kåge (Capital Markets), Mathilda Persson (Corporate Commercial), Rebecka Målquist (Intellectual Property) and Fanny Askelöf (Transaction Support Specialist).

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025